Legal & General Group Plc Takes Position in Danaher Corporation $DHR

Legal & General Group Plc bought a new stake in shares of Danaher Corporation (NYSE:DHR) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 4,205,461 shares of the conglomerate’s stock, valued at approximately $801,056,000. Legal & General Group Plc owned about 0.60% of Danaher as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the business. The Manufacturers Life Insurance Company bought a new position in shares of Danaher during the second quarter valued at about $70,176,000. The Manufacturers Life Insurance Company purchased a new position in shares of Danaher in the second quarter worth about $410,455,000. Jones Financial Companies Lllp bought a new stake in shares of Danaher in the 2nd quarter valued at about $107,000. Van Hulzen Asset Management LLC bought a new stake in shares of Danaher in the 2nd quarter valued at about $621,000. Finally, Broad Run Investment Management LLC purchased a new stake in Danaher during the 2nd quarter valued at about $13,512,000. 79.05% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have commented on DHR. Wells Fargo & Company decreased their price target on Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 22nd. Stifel Nicolaus dropped their price target on shares of Danaher from $260.00 to $220.00 and set a “buy” rating for the company in a research report on Wednesday, July 22nd. Evercore restated an “outperform” rating and issued a $230.00 price objective on shares of Danaher in a research report on Monday, July 6th. Weiss Ratings raised shares of Danaher from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, July 15th. Finally, Citigroup began coverage on shares of Danaher in a report on Tuesday, May 26th. They set a “buy” rating and a $230.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $228.91.

Danaher Price Performance

Shares of Danaher stock opened at $215.18 on Tuesday. The business has a 50 day moving average of $196.49 and a 200 day moving average of $192.39. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80. The company has a market cap of $151.27 billion, a PE ratio of 38.22, a P/E/G ratio of 2.72 and a beta of 0.78. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48.

Danaher (NYSE:DHR) last released its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.09. The business had revenue of $6.26 billion for the quarter, compared to analysts’ expectations of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The firm’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.77 earnings per share. As a group, equities research analysts forecast that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.